Patent application number | Description | Published |
20100105546 | Nickel-Based Reforming Catalysts - The present invention relates unique pore structures in nickel supported on alumina with the negligible formation of macropores. Incorporation of additional elements stabilizes the pore structure of the nickel supported on alumina. Additional element(s) were then further added into the nickel-supported materials. These additional element(s) further stabilize the pore structures under heating conditions. The improvements of pore structure stability under heating conditions and negligible presence of macropores limit the sintering of nickel metal to a mechanism of impeded diffusion. The negligible presence of macropores also limits the deposition of alkali metal hydroxide(s)/carbonate(s) on the outer shell of the catalyst pellet in the molten carbonate fuel cells. Both the negligible presence of macropores and improvement in pore structure stability allow for prolonging the catalyst life of these nickel supported on alumina catalysts of the present invention for reforming hydrocarbons. | 04-29-2010 |
20100298452 | Proton-Conducting Polymer with a Two-Dimensional Backbone of Metal-Oxygen Bonding - The present invention relates a new proton-conducting polymer with a two dimensional backbone with metal-oxygen bonding. The metal ion in the backbone of the proton-conducting polymer of the present invention comprises elements from Group IIIA, IVA, VA, IIIB, IVB, VB, VIB, lanthanides, etc in the Chemical Periodic Table. It is more preferred for the metal ion of the proton-conducting polymer of the present invention to be silicon, aluminum, boron, gallium, indium, tin, antimony, bismuth, titanium, or zirconium. It is further preferred that the backbone of the proton-conducting polymer of the present invention comprises silicon, aluminum, boron, zirconium, or titanium. It is further preferred that the proton-conduction polymer of the present invention comprises silicon in its two dimensional backbone. The backbone of the proton-conducting polymer of the present invention is chemically stable to attacks from the hydroxyl free radicals in the fuel cells. The invented polymer with a two dimensional backbone of metal-oxygen bonding is thermally stable for high temperature usage as a proton-exchange membrane for proton-exchange membrane fuel cells. The polymer with a two dimensional backbone of metal-oxygen bonding is also flexible and ductile enough to allow successful fabrication of the invented material into membrane-electrode-assembly for fuel cells. The flexibility and conductivity of the proton-conducting polymer of the present invention also allow the proton-exchange membrane fuel cell to have a long lifespan with minimal issues in membrane delamination and denaturing during fuel cell operation at a high temperature. | 11-25-2010 |
20130053237 | NICKEL-BASED REFORMING CATALYST - The present invention relates unique pore structures in nickel supported on alumina with the negligible formation of macropores. Incorporation of additional elements stabilizes the pore structure of the nickel supported on alumina. Additional element(s) were then further added into the nickel-supported materials. These additional element(s) further stabilize the pore structures under heating conditions. The improvements of pore structure stability under heating conditions and negligible presence of macropores limit the sintering of nickel metal to a mechanism of impeded diffusion. The negligible presence of macropores also limits the deposition of alkali metal hydroxide(s)/carbonate(s) to the outer shell of the catalyst pellet. Both of the negligible presence of macropores and improvement in pore structure stability allow for prolonging the catalyst life of these nickel supported on alumina catalysts of the present invention for reforming hydrocarbons. | 02-28-2013 |
Patent application number | Description | Published |
20120003888 | BIOADHESIVE CONSTRUCTS WITH POLYMER BLENDS - The invention describes substrates, such as prosthetics, films, nonwovens, meshes, etc. that are treated with a bioadhesive polymer blend. The bioadhesive includes polymeric substances that have phenyl moieties with at least two hydroxyl groups. The bioadhesive blend constructs can be used to treat and repair, for example, hernias and damaged tendons. | 01-05-2012 |
20120116424 | ADHESIVE COMPOUNDS AND METHODS USE FOR HERNIA REPAIR - The invention describes new synthetic medical adhesives and films which exploit the key components of natural marine mussel adhesive proteins. | 05-10-2012 |
20120149849 | MULTI-ARMED CATECHOL COMPOUND BLENDS - The invention describes families of compounds that utilize multihydroxyl phenyl groups to provide adhesive properties. Selection of the multihydroxy phenyl group along with linkers or linking groups and the linkages between the linkers or linking groups with polyalkylene oxides, provides materials that can be engineered to afford controllable curing time, biodegradation and/or swelling. | 06-14-2012 |
20120179083 | THIN FILM COMPOSITIONS AND METHODS OF SYNTHESIS AND USE THEREFOR - The invention relates generally to thin-film adhesive materials suitable for various applications. In particular, the present invention provides pliable viscoelastic thin-films configured to form strong water-resistant adhesive bonds to various surface types. | 07-12-2012 |
Patent application number | Description | Published |
20120002717 | METHOD AND SYSTEM FOR LIVE STREAMING VIDEO WITH DYNAMIC RATE ADAPTATION - A live streaming system/method provides cross platform live streaming capabilities to mobile devices. A file format compatible with legacy HTTP infrastructure is used to deliver media over a persistent connection. Legacy client media players can dynamically change the encoded rate of the media delivered over a persistent connection. Standard HTTP servers may be used without modification, leveraging standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. | 01-05-2012 |
20120004960 | METHOD AND SYSTEM FOR EFFICIENT STREAMING VIDEO DYNAMIC RATE ADAPTATION - A streaming media system employs dynamic rate adaptation. The method includes a file format compatible with legacy HTTP infrastructure to deliver media over a persistent connection. The method further includes the ability for legacy client media players to dynamically change the encoded delivery rate of the media over a persistent connection. The method provided works transparently with standard HTTP servers, requiring no modification and leverages standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. A system is also specified for implementing a client and server in accordance with the method. | 01-05-2012 |
20120005364 | SYSTEM AND METHOD FOR NETWORK AWARE ADAPTIVE STREAMING FOR NOMADIC ENDPOINTS - In a system for streaming data over a network, the type and rate of streaming are automatically varied based on available network bandwidth. Video media is transcoded into different bit rate encodings that are divided into segment files. Segments are sent from a network-aware adaptive streaming (NAAS) server and reassembled and presented to a media player at a client device. The system may download additional segment files ahead of time from multiple NAAS servers to increase throughput. A playback status (“bookmark”) may be maintained to keep track of what the user has viewed and to allow the user to continue playing from where the user left off. The user may continue watching from the bookmark point on the same device or on a different device. | 01-05-2012 |
20120005365 | METHOD AND SYSTEM FOR EFFICIENT STREAMING VIDEO DYNAMIC RATE ADAPTATION - A streaming media system employs dynamic rate adaptation. The method includes a file format compatible with legacy HTTP infrastructure to deliver media over a persistent connection. The method further includes the ability for legacy client media players to dynamically change the encoded delivery rate of the media over a persistent connection. The method provided works transparently with standard HTTP servers, requiring no modification and leverages standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. A system is also specified for implementing a client and server in accordance with the method. | 01-05-2012 |
20120005366 | METHOD AND APPARATUS FOR RETRIEVING AND RENDERING LIVE STREAMING DATA - A live streaming system/method provides cross platform live streaming capabilities to mobile devices. A file format compatible with legacy HTTP infrastructure is used to deliver media over a persistent connection. Legacy client media players can dynamically change the encoded rate of the media delivered over a persistent connection. Standard HTTP servers may be used without modification, leveraging standard media players embedded in mobile devices for seamless media delivery over wireless networks with high bandwidth fluctuations. | 01-05-2012 |
20120011267 | LIVE STREAMING MEDIA DELIVERY FOR MOBILE AUDIENCES - A live streaming system/method provides cross platform live streaming capabilities to mobile devices. The live streaming system includes a live streaming recorder operative to (1) capture a live media stream generated by a live media source and save the captured live media stream as a recorded stream in a recorded media file, and (2) transcode the recorded stream into a plurality of transcoded media files of respective different media encoding formats. The system further includes a stream distribution subsystem operative to generate a plurality of distributed media streams each generated from one or more of the transcoded media files, each distributed media stream being delivered to a corresponding set of the mobile endpoint devices. | 01-12-2012 |
20120265892 | METHOD AND SYSTEM FOR SECURE AND RELIABLE VIDEO STREAMING WITH RATE ADAPTATION - A system for media delivery includes a server-side proxy for aggregating and encrypting stream data for efficient HTTP-based distribution over an unsecured network. A client-side proxy decrypts and distributes the encapsulated stream data to client devices. A multicast-based infrastructure may be used for increased scalability. The encoded rate of the media delivered over the persistent HTTP proxy connections may be dynamically adapted. The client-side proxy may be integrated within a mobile device for maximum network security and reliability. | 10-18-2012 |
20130097309 | METHOD AND APPARATUS FOR CARRIER CONTROLLED DYNAMIC RATE ADAPTATION AND CLIENT PLAYOUT RATE REDUCTION - A method and system is provided for controlling bandwidth rate limiting and client rendering rate limiting in a video delivery network. The method provides network service providers with a means for overriding video delivery data rates selected through dynamic client bitrate adaptation, as well as video data rendering rates of the clients, to limit the impact of network congestion. A system is also specified for implementing a client and a proxy computer in accordance with the method. The system works transparently with standard HTTP-based video delivery systems and includes an HTTP proxy cache infrastructure to support bandwidth rate limiting and client rending rate limiting. The system further provides for administrative overrides of client bitrate selection and client bandwidth usage. | 04-18-2013 |
20140149210 | METHOD AND SYSTEM FOR AD INSERTION IN OVER-THE-TOP LIVE MEDIA DELIVERY - A method is provided for performing targeted ad insertion in over-the-top delivery of content by detecting ad replacement opportunities in a live content stream and preparing the content for seamless replacement with segmented HTTP adaptive streaming delivery. The method includes provisions for multi-stage proxy-based segment replacement for targeted ad delivery. The method provided works transparently with standard HTTP adaptive streaming clients. A system is also specified for implementing a client and server content delivery infrastructure in accordance with the provisions of the method. | 05-29-2014 |
20140150019 | METHOD AND SYSTEM FOR AD INSERTION IN OVER-THE-TOP LIVE MEDIA DELIVERY - A method is provided for performing targeted ad insertion in over-the-top delivery of content by detecting ad replacement opportunities in a live content stream and preparing the content for seamless replacement with segmented HTTP adaptive streaming delivery. The method includes provisions for multi-stage proxy-based segment replacement for targeted ad delivery. The method provided works transparently with standard HTTP adaptive streaming clients. A system is also specified for implementing a client and server content delivery infrastructure in accordance with the provisions of the method. | 05-29-2014 |
Patent application number | Description | Published |
20100068168 | THERMAL RESPONSIVE POLYMER SILOXANES, COMPOSITIONS, AND METHOD AND APPLICATIONS RELATED THERETO - The invention relates to materials comprising siloxanes, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. | 03-18-2010 |
20100098761 | Polymer Compositions For Biomedical And Material Applications - The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules. | 04-22-2010 |
20100280561 | Thermal-Responsive Polymer Networks, Compositions, And Methods And Applications Related Thereto - The invention relates to materials comprising polymer network containing siloxanes or organic-based core structures, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to an organic core functionalized with polymers. In another embodiment, organic core-polymer conjugates comprise polylactone segments. The organic core-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments | 11-04-2010 |
20140058058 | MONOMERS AND POLYMERS FOR FUNCTIONAL POLYCARBONATES AND POLY(ESTER-CARBONATES) AND PEG-CO-POLYCARBONATE HYDROGELS - The invention generally relates to functional polymers and hydrogels. More particularly, the invention provides versatile monomers and polymers with well-defined functionalities, e.g., polycarbonates and poly(ester-carbonates), compositions thereof, and methods for making and using the same. The invention also provides cytocompatible poly(ethylene glycol)-co-polycarobonate hydrogels (e.g., crosslinked by copper-free, strain-promoted “click” chemistry). | 02-27-2014 |
20140255333 | THERMAL RESPONSIVE POLYMER SILOXANES, COMPOSITIONS, AND METHOD AND APPLICATIONS RELATED THERETO - The invention relates to materials comprising siloxanes, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. | 09-11-2014 |
20140357806 | THERMAL-RESPONSIVE POLYMER NETWORKS, COMPOSITIONS, AND METHODS AND APPLICATIONS RELATED THERETO - The invention relates to materials comprising polymer network containing siloxanes or organic-based core structures, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to an organic core functionalized with polymers. In another embodiment, organic core-polymer conjugates comprise polylactone segments. The organic core-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. | 12-04-2014 |
Patent application number | Description | Published |
20090099222 | Modulators of muscarinic receptors - The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases. | 04-16-2009 |
20110059936 | C-MET PROTEIN KINASE INHIBITORS - The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders. | 03-10-2011 |
20120039849 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 02-16-2012 |
20130281431 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 10-24-2013 |
20140045869 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 02-13-2014 |
Patent application number | Description | Published |
20080305122 | Ii-Key/antigenic epitope hybrid peptide vaccines - Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less. | 12-11-2008 |
20090060889 | Ii-RNAi involved Ii suppression in cancer immunotherapy - Provided are compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated. The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has a synergistic effect on Ii inhibition. Furthermore, specific promoters for driving Ii-RNAi expression are critical for the activity of Ii-RNAi in different types of cells. Active Ii-RNAi sequences were cloned into plasmids in which Ii-RNAi sequences are driven by either a CMV or an EF-1α promoter. Compositions and methods are disclosed for inhibiting Ii and treating cancer. Provided are siRNAs and expression constructs comprising DNA sequences which encode siRNAs effective to inhibit Ii expression, cells containing such DNA constructs or siRNAs, and methods for use of the same. | 03-05-2009 |
20090060936 | Ii-Key/Her-2/neu hybrid cancer vaccine - Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide. | 03-05-2009 |
20100080817 | HUMAN PAPILLOMAVIRUS / Ii-KEY HYBRIDS AND METHODS OF USE - The present invention is directed towards compositions comprising Ii-Key/HPV hybrid peptides. The hybrid peptides of the present invention are effective in the generation of CD4+ helper T cell immune responses directed towards the specific HPV epitopes encoded in the hybrid peptide. The inclusion of the Ii-key peptide in the hybrid causes the peptide to have greater immunogenicity as compared to control peptide. The inclusion of Ii-Key/HPV hybrid in a peptide vaccine formulation composing both HPV hybrid and HPV CTL epitope peptide (administered concurrently or sequentially) leads to a greater CTL activity against HPV CTL epitopes. The hybrid peptides of the present invention may be useful, for example, for the immunization of subjects against HPV. | 04-01-2010 |
20100150953 | Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE - Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide. | 06-17-2010 |
20100255019 | Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE - Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK [SEQ ID NO.: 2] residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide. | 10-07-2010 |
20100291145 | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES - Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope, or said encoded protein or peptide. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide, or said encoded protein or peptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less. | 11-18-2010 |
Patent application number | Description | Published |
20090295364 | Methods of Using a Nanotransfer Printing Stamp Having Conductively Coated Sidewalls - Methods and apparatuses for generating electrically-conductive and/or semi-conductive films, and more specifically, methods and apparatuses for generating conductive and/or semi-conductive films having nanoscale features are provided. In one embodiment, an electrically-conductive or semi-conductive film (e.g., a gold layer of less than 50 nanometer thickness) is provided on a substrate (e.g., a poly(dimethylsiloxane) (PDMS) stamp). The substrate may optionally include patterns or features having raised and recessed portions. A first portion of the film may be removed from the substrate, e.g., by methods such as physically contacting the first portion of the film with a surface to which the first portion preferentially adheres. This process can leave a second portion of the film remaining on the substrate. In some embodiments, the second portion includes at least one region having a dimension substantially parallel to a portion of the substrate i.e., of less than 50 nanometers. The second portion of the film may be used to establish electrical communication with an electrical contact. Advantageously, electrically-conductive and/or semi-conductive films having nanoscale features can be fabricated over large areas (e.g., areas greater than 1 cm | 12-03-2009 |
20130177749 | NANOSTRUCTURES - A method for producing a matrix containing nanostructures. The method includes obtaining a layer having a thickness of 10 nm-100 μm, wherein the layer contains organic macromolecules arranged in a nanopattern, staining the layer with a solution containing a salt so that a portion of the salt is retained in the layer, and removing the organic mcaromolecules from the layer to form a matrix containing nanostructures. Also within the scope of this invention are nanostructures prepared by this method. | 07-11-2013 |
Patent application number | Description | Published |
20080213860 | Nicking Endonuclease Methods and Compositions - A nicking endonuclease is described which has an amino acid sequence with at least 70% identity to SEQ ID NO:6 and comprising a mutation at least one of an arginine or gutamic acid corresponding to position 507 and position 546 respectively in SEQ ID NO:6. | 09-04-2008 |
20090029376 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions include restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 01-29-2009 |
20090029418 | METHOD FOR CLONING AND EXPRESSION OF STUI RESTRICTION ENDONUCLEASE AND STUI METHYLASE IN E. COLI - The present invention relates to compositions including: (1) isolated DNA encoding the Stul restriction endonuclease and isolated DNA encoding cognate and non-cognate methylase; (2) vectors and cells containing the isolated DNA; and (3) methods for producing the Stul restriction endonuclease. | 01-29-2009 |
20090280528 | Method for Cloning and Expression of NruI Restriction Endonuclease - Recombinant DNA encoding NruI- and SboI-like restriction endonucleases and methylases and their amino acid sequences are provided as well as methods for expressing the enzymes in transformed host cells and purifying the enzymes. | 11-12-2009 |
20110076720 | NICKING ENDONUCLEASE METHODS AND COMPOSITIONS - A nicking endonuclease is described which has an amino acid sequence with at least 70% identity to SEQ ID NO:6 and comprising a mutation at least one of an arginine or gutamic acid corresponding to position 507 and position 546 respectively in SEQ ID NO:6. | 03-31-2011 |
20110151450 | High Fidelity Restriction Endonucleases - Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer. | 06-23-2011 |
20130115676 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130115677 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130115678 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130115679 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130115680 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130115681 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-09-2013 |
20130122568 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-16-2013 |
20130130935 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 05-23-2013 |
20130190209 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 07-25-2013 |
20140154676 | High Fidelity Restriction Endonucleases - Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer. | 06-05-2014 |
20140154778 | High Fidelity Restriction Endonucleases - Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer. | 06-05-2014 |
20140154779 | High Fidelity Restriction Endonucleases - Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer. | 06-05-2014 |
20140154780 | High Fidelity Restriction Endonucleases - Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer. | 06-05-2014 |
Patent application number | Description | Published |
20100105546 | Nickel-Based Reforming Catalysts - The present invention relates unique pore structures in nickel supported on alumina with the negligible formation of macropores. Incorporation of additional elements stabilizes the pore structure of the nickel supported on alumina. Additional element(s) were then further added into the nickel-supported materials. These additional element(s) further stabilize the pore structures under heating conditions. The improvements of pore structure stability under heating conditions and negligible presence of macropores limit the sintering of nickel metal to a mechanism of impeded diffusion. The negligible presence of macropores also limits the deposition of alkali metal hydroxide(s)/carbonate(s) on the outer shell of the catalyst pellet in the molten carbonate fuel cells. Both the negligible presence of macropores and improvement in pore structure stability allow for prolonging the catalyst life of these nickel supported on alumina catalysts of the present invention for reforming hydrocarbons. | 04-29-2010 |
20100298452 | Proton-Conducting Polymer with a Two-Dimensional Backbone of Metal-Oxygen Bonding - The present invention relates a new proton-conducting polymer with a two dimensional backbone with metal-oxygen bonding. The metal ion in the backbone of the proton-conducting polymer of the present invention comprises elements from Group IIIA, IVA, VA, IIIB, IVB, VB, VIB, lanthanides, etc in the Chemical Periodic Table. It is more preferred for the metal ion of the proton-conducting polymer of the present invention to be silicon, aluminum, boron, gallium, indium, tin, antimony, bismuth, titanium, or zirconium. It is further preferred that the backbone of the proton-conducting polymer of the present invention comprises silicon, aluminum, boron, zirconium, or titanium. It is further preferred that the proton-conduction polymer of the present invention comprises silicon in its two dimensional backbone. The backbone of the proton-conducting polymer of the present invention is chemically stable to attacks from the hydroxyl free radicals in the fuel cells. The invented polymer with a two dimensional backbone of metal-oxygen bonding is thermally stable for high temperature usage as a proton-exchange membrane for proton-exchange membrane fuel cells. The polymer with a two dimensional backbone of metal-oxygen bonding is also flexible and ductile enough to allow successful fabrication of the invented material into membrane-electrode-assembly for fuel cells. The flexibility and conductivity of the proton-conducting polymer of the present invention also allow the proton-exchange membrane fuel cell to have a long lifespan with minimal issues in membrane delamination and denaturing during fuel cell operation at a high temperature. | 11-25-2010 |
20130053237 | NICKEL-BASED REFORMING CATALYST - The present invention relates unique pore structures in nickel supported on alumina with the negligible formation of macropores. Incorporation of additional elements stabilizes the pore structure of the nickel supported on alumina. Additional element(s) were then further added into the nickel-supported materials. These additional element(s) further stabilize the pore structures under heating conditions. The improvements of pore structure stability under heating conditions and negligible presence of macropores limit the sintering of nickel metal to a mechanism of impeded diffusion. The negligible presence of macropores also limits the deposition of alkali metal hydroxide(s)/carbonate(s) to the outer shell of the catalyst pellet. Both of the negligible presence of macropores and improvement in pore structure stability allow for prolonging the catalyst life of these nickel supported on alumina catalysts of the present invention for reforming hydrocarbons. | 02-28-2013 |
Patent application number | Description | Published |
20110136682 | ANTENNARY FUCOSYLATION IN GLYCOPROTEINS FROM CHO CELLS - The present invention provides methods of evaluating CHO cells and producing recombinant glycoproteins. | 06-09-2011 |
20110287465 | CHARACTERIZATION OF O-LINKED GLYCANS - The present disclosure provides methods for analyzing structure and/or composition of glycoproteins and glycans of glycoproteins. Such methods can include subjecting a glycoprotein preparation to a condition that removes at least one O-linked glycan from the glycoprotein. Such methods can include subjecting a glycoprotein preparation to a condition that releases an N-glycan from the glycoprotein, e.g., prior to subjecting the glycoprotein to a condition that releases an O-glycan from the glycoprotein. | 11-24-2011 |
20140045204 | EVALUATION OF COPOLYMER DIETHYLAMIDE - Methods of analyzing glatiramer acetate (GA) or a polymeric precursor thereof are provided. The methods can include determining a level of one or more diethylamide-modified amino acids in a sample comprising GA or a polymeric precursor thereof, and selecting at least a portion of the sample based on the assessment of the one or more diethylamide-modified amino acids in the sample. | 02-13-2014 |
20140046024 | EVALUATION OF COPOLYMER DIETHYLAMIDE - Methods of analyzing glatiramer acetate (GA) or a polymeric precursor thereof are provided. The methods can include determining a level of one or more diethylamide-modified amino acids in a sample comprising GA or a polymeric precursor thereof, and selecting at least a portion of the sample based on the assessment of the one or more diethylamide-modified amino acids in the sample. | 02-13-2014 |
Patent application number | Description | Published |
20100075325 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 03-25-2010 |
20100105051 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 04-29-2010 |
20100291068 | NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided. | 11-18-2010 |
20110092388 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 04-21-2011 |
Patent application number | Description | Published |
20090042828 | METHODS AND COMPOSITIONS FOR TREATING GAIN-OF-FUNCTION DISORDERS USING RNA INTERFERENCE - The present invention relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS), with RNAi agent. The invention further provides RNAi resistant replacement genes containing mismatches with their respective RNAi agents. The invention also provides for vectors that express RNAi agent and RNAi resistant replacement gene of the present invention. | 02-12-2009 |
20110160286 | ALLELE-SPECIFIC RNA INTERFERENCE - Human diseases caused by dominant, gain-of-function mutations develop in heterozygotes bearing one mutant and one wild-type copy of a gene. Because the wild-type gene often performs important functions, whereas the mutant gene is toxic, any therapeutic strategy must selectively inhibit the mutant while retaining wild-type gene expression. The present invention includes methods of specifically inhibiting the expression of a mutant allele, while preserving the expression of a co-expressed wild-type allele using RNAi, a therapeutic strategy for treating genetic disorders associated with dominant, gain-of-function gene mutations. The invention also includes small interfering RNAs (siRNAs) and small hairpin RNAs (shRNAs) that selectively suppress mutant, but not wild-type, expression of copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS). The present invention further provides asymmetric siRNAs and shRNAs with enhanced efficacy and specificity and mediating RNAi. | 06-30-2011 |
20130195801 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders. | 08-01-2013 |
20140044722 | ANTI-SOD1 ANTIBODIES AND USES THEREOF - The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS. | 02-13-2014 |
20140335054 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders. | 11-13-2014 |